BNTX has shown recent bullish momentum, with a 5.51% increase in the regular market on 2025-03-24, closing at $99.5. The stock's price trend indicates potential upside, supported by positive analyst sentiment.

Valuation Analysis:

BNTX currently has a market cap of $23.87B and a P/E ratio of -32.95, reflecting current profitability challenges. Despite this, analysts maintain a positive outlook, with a mean price target of $139, suggesting significant upside potential.

Analyst Sentiment:

Major firms like Morgan Stanley and Citigroup have maintained Buy ratings on BNTX, with price targets ranging from $139 to $145. This indicates strong confidence in the company's future prospects, particularly in its oncology pipeline.

Insider Activity:

Recent insider selling has increased, which may signal caution. However, this could also be part of strategic portfolio management and not necessarily a negative indicator.

Conclusion:

Given the positive analyst sentiment and recent price strength, BNTX presents a compelling buy opportunity for long-term growth, particularly with its promising pipeline. However, the negative P/E ratio and insider selling warrant caution. It may be prudent to monitor the stock for further momentum confirmation before making a decision.

What is price prediction 2025 for BNTX Stock?

Price Prediction for BNTX Stock in 2025

Based on current trends and analysis, BNTX stock is predicted to reach $135 by the end of 2025. This prediction is supported by strong analyst sentiment, with Morgan Stanley and other firms maintaining Buy ratings and price targets ranging from $139 to $171. The stock's current undervaluation and positive developments in its pipeline further strengthen this outlook.

What is surpport and resistant level for BNTX Stock?

The S1 support level for BNTX Stock is $87.92 ,The R1 resistant level for BNTX Stock is $100.25.

What is the current price of BNTX Stock?

As of the end of day on 2025-04-02, the price of BNTX Stock was $92.8.

What is the target price of BNTX Stock?

The target price for BNTX Stock according to analyst rating is 137.93, with the highest price target at 171.00 and the lowest at 110.00. Analysts have a Strong Buy rating on BNTX Stock overall.

What is the market cap of Biontech SE?

The market cap of BNTX is $22.4B.

Is Biontech SE (BNTX) overvalued?

Analysis and Insights

Valuation Metrics:

BNTX's current valuation metrics suggest potential overvaluation. The stock has a P/E ratio of -32.95, indicating negative earnings, and a high P/S ratio of 15.91%. The EV/EBITDA ratio of 8.47 is also elevated compared to industry peers. Additionally, the price-to-book ratio of 7.33 suggests a premium valuation relative to book value.

Technical Analysis:

The stock is currently trading below its 50-day and 200-day moving averages, with an RSI of 34.44, indicating oversold conditions. The MACD is negative, suggesting bearish momentum. Recent price action shows resistance at the Fibonacci levels, with the stock struggling to break above $105.33.

Analyst Sentiment:

Analysts are mixed on BNTX, with a consensus rating of "Buy" but varying price targets. The average price target is $145, representing a 48.77% upside from current levels. However, insider sentiment is negative, with increased selling activity.

Conclusion:

BNTX appears overvalued based on its high P/S and P/B ratios, negative earnings, and negative ROE. While analysts remain optimistic, technical indicators and insider selling suggest caution. Investors should monitor the stock's ability to improve profitability and reduce valuation multiples.

What is Biontech SE (BNTX)'s business?

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

What is price prediction 2030 for BNTX Stock?

The price prediction for BNTX stock by 2030 is estimated to range between $200 and $250. This forecast is based on the company's strong oncology pipeline, particularly the promising late-stage asset BNT327, which could generate significant revenue if approved. Additionally, BioNTech's diversification beyond COVID-19 vaccines and its strong financial position support long-term growth.